Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to audiocast for Devyser’s Q2 report 2023

On Wednesday August 23, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2023 report (which will have been published earlier on August 23, at 07.30 CET). The presentation will be held in English.    Dial-in number to the teleconference and a conference ID will be received by registering on the link below:https://conference.financialhearings.com/teleconference/?id=200933   The presentation will also be webcast and can be accessed from the following web address:  https://ir.financialhearings.com/devyser-diagnostics-q2-2023   Speakers: CEO

BEWI – Invitation to presentation of results for the second quarter of 2023

BEWI, a leading provider of packaging, components, and insulation solutions, will announce its results for the second quarter of 2023 on Thursday 17 August 2023. The results will be available from 07:00 am CEST at the company's homepage, www.bewi.com and Oslo Børs' news site, www.newsweb.no CEO Christian Bekken and CFO Marie Danielsson will present the results from 10:00 through a live webcast. The link to the webcast will be available from BEWI’s website  www.bewi.com/investors/reports-presentations/. It will be possible to post questions through the webcast, and a recording will be

Aqilion has completed Phase 1 study with AQ280 within the Regulus program

AQILION (publ) announces today that it has successfully completed the first clinical study in humans within the Regulus program. The Phase 1 ARIA-1 study was conducted to evaluate the safety, tolerability, and pharmacokinetics of the drug candidate AQ280 in healthy adult participants, given in single dose and repeated dosing. The preliminary study results are expected in Q4 2023.Within the Regulus program, Aqilion is developing AQ280, which is a super selective JAK1 inhibitor, as a treatment of the chronic disease eosinophilic esophagitis. Since August last year, healthy volunteers have

Billerud introduces strong coated white top kraftliners to the US market

As part of the company’s expansion into the North American market, Billerud, a world-leading manufacturer of superior paper and packaging materials, is introducing its portfolio of coated liners to the US market. This introduction will enable great improvements in sustainability and cost performance for both packaging converters and brand owners.[Billerud Coated Liners ] Example of Billerud's Coated Liners."Strong liners with excellent printability don’t need to be thick and heavy. With 100% virgin fibers and a multi-layer construction, Billerud´s coated liners are so strong that

Europa Universalis IV Celebrates 10th Anniversary

Paradox Marks the Decade with Community Music PackSTOCKHOLM - 14 August 2023 - Europa Universalis IV, Paradox Interactive’s flagship historical grand strategy game, celebrates its 10th anniversary this month. Ever since its release in August 2013, EU4 has been a favorite with desktop rulers and history buffs, with a nearly infinite array of possible pasts. Set in the four centuries between 1444 and 1821, Europa Universalis IV lets you play as any nation in history through that time span as the world moves through the Renaissance and Reformation to the Enlightenment and Age of Revolutions.

Detection Technology initiates change negotiations to improve its operational efficiency and profitability

Detection Technology Plc company announcement 14 August 2023 at 11:15 (EEST) Detection Technology initiates change negotiations to improve its operational efficiency and profitability Detection Technology Plc announced in its half-year report that it has taken measures to improve its operational efficiency and profitability. As a part of these measures the company initiates change negotiations in Finland in accordance with the Finnish Act on Co-operation within Undertakings. The scope of the change negotiations includes the company's all senior salaried employees in Finland, a

Invitation to Latour’s presentation of the half year report for 2023

Latour will publish the interim report for the second quarter on 21 August 2023, at 08.30 (CEST).President and CEO Johan Hjertonsson will present the report and answer to questions together with CFO Anders Mörck on the same day at 10.00 (CEST) in a webcasted telephone conference.   WebcastVia the webcast you are able to ask written questions.If you wish to participate via webcast, please use the link: https://ir.financialhearings.com/latour-q2-2023 TeleconferenceYou can ask questions verbally via the teleconference.If you wish to participate via teleconference, please

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS14 August 2023 at 11:15NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: PM Ruukki OyPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Markku KankaalaPosition: Member of the BoardIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 36612/4/4 ____________________________________________Transaction date: 2023-08-11Outside a trading venue

Notice to Extraordinary General Meeting in Cinis Fertilizer AB

The shareholders of Cinis Fertilizer AB, reg. no 559154-0322, are hereby summoned to the extraordinary general meeting to be held on 30 August 2023 at 10:00 a.m. CEST on Advokatfirman Schjødt at Hamngatan 27, Stockholm, Sweden. The entrance to the meeting and registration will open at 09:30 a.m. CEST.The board of directors has decided, pursuant to the company’s articles of association, that shareholders shall also have the right to exercise their voting rights by postal voting. Shareholders may therefore choose to exercise their voting rights at the general meeting by attending in person,

New study shows Probi strain supports and improves cognitive performance

In a newly published study Probi´s proprietary strain L. plantarum HEAL9 (HEAL9™) was shown to significantly improve cognitive performance. The result of the study is encouraging ahead of Probi's launch of a new product in the gut-brain area. Consumer interest in mental health and wellness is rapidly growing and the understanding of the important connection between the microbiome in the gut and mood, cognition and mental health continues to increase. Probiotic supplements supporting mental health and wellness are forecasted to have a significant market growth of 44% in the coming 10

Spinnova receives Business Finland R&D grant for developing SPINNOVA® fibre from new raw materials

SPINNOVA PLC, PRESS RELEASE 14 AUGUST 2023 AT 11 A.M. EEST   Spinnova receives Business Finland R&D grant for developing SPINNOVA® fibre from new raw materials   Spinnova has received a grant of maximum EUR 1.9 million for its research and development (R&D) work from Business Finland for the period 15 April 2023 – 14 April 2025. The grant amount represents 50% of the project’s total cost estimate totalling EUR 3.9 million. The product development project aims for pilot-scale production of SPINNOVA® fibre from textile and agricultural waste streams. The refining environment to

Dicot confirms planned start date in August for its phase 1 study

Press release: Uppsala, August 14, 2023. The potency drug developer Dicot announces that the decision from the Swedish Medical Products Agency on the clinical trial application is expected within two weeks and that the company is ready to start the study in August according to the previously communicated schedule.Dicot has completed all preparations required for the start of the planned phase 1 trial of its potency drug candidate LIB-01. The round of questions with the Medical Products Agency and the Ethical Review Authority, which is part of the application process, was completed during

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 115 - 14 AUGUST 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Compliance with MAR

Menhaden Resource Efficiency PLC (the “Company”) LEI: 2138004NTCUZTHFWXS17     Compliance with Market Abuse Regulation – Closed Period   14 August 2023   The Company confirms that:   a) all inside information which the Directors and Company may have had has been notified to a Regulated Information Service (“RIS”);   b) the Company’s net asset value per share is calculated and announced through a RIS on a daily basis; and   c) the Company has no reason to believe that there will be any material difference between the net asset value per share as

Irisity reappoints Anna Forsberg as new Interim Chief Financial Officer

Irisity AB (publ), a leading AI video analytics provider, is pleased to announce the return of Anna Forsberg as its Interim Chief Financial Officer, effective September 1, 2023. Anna Forsberg previously served with distinction in this capacity from February 2022 to November 2022.Irisity reappoints Anna Forsberg as new Interim Chief Financial Officer.     Irisity AB (publ), a leading AI video analytics provider, is pleased to announce the return of Anna Forsberg as its Interim Chief Financial Officer, effective September 1, 2023. Anna Forsberg previously served with distinction in

Kid ASA - Invitation to presentation of Second quarter 2023 results

Lier, 14 August 2023: Kid ASA will release its second quarter 2023 results on Thursday 24 August 2023. The quarterly report and presentation material will be available on http://investor.kid.no and http://newsweb.no from 07:30 CEST. The results will be presented at 09:00 CEST by CEO Anders Fjeld and CFO Mads Kigen at the offices of Arctic Securities, Haakon VIIs gate 5, 0161 Oslo. The presentation will be broadcasted as a live webcast in English and a recorded version will be made available at http://investor.kid.no. Please sign up for the webcast with the following link and you can

Desert Control Q2 2023 Report and Interim Financial Results | Webcast presentation 24 August 2023 10:00 CET

ISSUER DESERT CONTROL AS Sandnes, Norway 14 August 2023: Desert Control Q2 2023 Report and InterimFinancial Result will be released on Thursday 24 August 2023 at 07.30 AM CentralEuropean Time (Oslo)The Q2 Report and presentation will be made available athttps://www.desertcontrol.com/investorsA webcast presentation in English will be hosted on Thursday 24 August 2023 at10.00 AM Central European Time.Registration:https://go.desertcontrol.com/Q2-2023After the presentation, there will be a Q&A session. Questions can be submittedin advance to leonard.chaparian@

Repurchase of Truecaller B shares in week 32, 2023

During 7 August 2023 and 11 August 2023 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 1,025,000 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 7 June 2023. The share buyback programme will run between 7 June up until the 2024 AGM which will be held in May 2024, and is carried out in accordance “Emittentregelverket”.   On the Annual General Meeting 2023 the Board was authorized to buy back B-shares up until

Valmet to supply machine vision systems to Shanxi Qiangwei Paper in China

Valmet Oyj’s trade press release on August 14, 2023 at 9:40 a.m. EESTValmet has received an order from Shanxi Qiangwei Paper Co., Ltd. to supply machine vision systems for Qiangwei’s paper machine PM 6. The scope of supply includes a Valmet IQ Web Inspection System, a Valmet IQ Web Monitoring System and winder control with target-stop functionality. The investment aims to improve the operating efficiency and optimize the final paper quality of the PM 6. The order was included in Valmet’s orders received of the second quarter 2023. The delivery will take place in the first quarter 2024.

GARO Entity PRO – third-party certified wall box with unique security solution

GARO has elected to third-party certify GARO Entity Pro to ensure that the product is quality assured and that it adheres to current directives, laws and standards, and passes the stringent testing carried out during product development. GARO Entity Pro thus has an approved unique built-in solution for electrical safety in the wall box. End users, customers and installation engineers can therefore be confident that the product delivers what it promises.    “Throughout the GARO Entity development project, we have had an uncompromising focus on product safety. This has been our main

Veg of Lund AB - Interim report Q2 2023

Increased sales at lower costApril–June 2023 · Net sales amounted to TSEK 1,4580 (1 070). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK-7,824 (-11,291), and EBIT amounted to TSEK -7,842 (-11,343). · Net profit amounted to TSEK -8,069 (-11,183). January–June 2023 · Net sales amounted to TSEK 3,281 (1 524). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK-16,102 (-29,004), and EBIT amounted to TSEK -16,173 (-29,107). · Net profit amounted to TSEK -16,687 (-29,182). Summary of the Group’s

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

· Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment · The patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor reduction maintained · Consistently good safety and tolerability profile Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the ongoing phase 2a

There are no items matching the current filter
There are no more items matching the current filter
Back to top